BEAM - BEAM

Beam Therapeutics 株価情報 (NASDAQ: BEAM)

最新ニュース Beam Therapeutics (NASDAQ:BEAM) 株価情報

BEAM THERAPEUTICS INC

Beam Inc.

NYSE

Beam Therapeutics

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Beam Therapeutics Inc

BEAM - United States Dollar

BEAM COMM HLDGS LTD by BEAM COMMUNICATIONS HLDGS LTD.

Beam Global

Beamr Imaging Ltd

BEAMZ INTERACTIVE INC by Beamz Interactive Inc

Beamz Interactive Inc

Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 Foundation 7th Global Research Conference and <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">10th Patient Congress</a>.
AATD is an inherited genetic disorder that can cause early onset emphysema and liver disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44218611/gene-edit-biotech-beam-therapeutics-touts-encouraging-data-from-early-stage-gene-therapy-study-in-genetic-disorder-raises-500-million-via-equity" rel="noreferrer noopener">Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity</a>
Initial safety and efficacy data from the Phase 1/2 trial of BEAM-302 were previously&nbsp;<a target="_blank" href="https://www.globenewswire.com/Tracker?data=DGjvxT5xtICCkQ8gwO3vYKCxk4cQeGEVsiyMQrfGuDK85hfJvOf0_YRSCN3D4S2uPdzWIKOzfsxza85TGOOOmoIkpgc1qwWR9HDfBTbthTKhQDPwQrYggdlqLEDXs4WjgwVKQ_WJgjueP5aZJLXesgIntByaC3vCddeZGNP6hOg60nlrLmP-9YVZC3BBCaMhoF_Q_HvldXOxFXwKhnaNyTK85Sj9OFVYNjcCdMA9MHs=&amp;tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">reported</a> in March 2025, establishing clinical proof of concept as a potential treatment for AATD and&nbsp;in vivo base editing.
Preliminary results from the first three single-ascending dose cohorts demonstrated that BEAM-302 was well tolerated.
Single doses of BEAM-302 led to durable dose-dependent correction of the disease-causing mutation and total AAT protein levels above the therapeutic threshold in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44656185/beam-therapeutics-presents-additional-data-for-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-" rel="noreferrer noopener">60 mg dose cohort</a>.
These previously reported data were included in the presentation, alongside updated biomarker data from the 60 mg cohort showing levels of corrected protein (M-AAT) and the mutant form of alpha-1 antitrypsin protein (Z-AAT) out to Day 28 for all three patients.
At Day 28, the proportion of corrected M-AAT reached a mean of 91% of total AAT in circulation, surpassing levels observed in patients with the MZ genotype where circulating M-AAT is typically ~80%.
In addition, treatment with BEAM-302 led to a mean decrease of 79% of circulating mutant Z-AAT from baseline as of Day 28.
Beam plans to continue the dose-escalation portion of Part A of the ongoing Phase 1/2 trial, including enrolling and dosing a fourth dose cohort of 75 mg, and expects to report further data at a medical conference in the second half of 2025.
In addition, the company plans to dose the first patient in Part B, including AATD patients with mild to moderate liver disease, in the second half of 2025.
The U.S. Food and Drug Administration recently cleared Beam Therapeutics&#8217; investigational drug application for BEAM-302, enabling the company to activate sites in the U.S. for its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44523407/beam-therapeutics-announces-clearance-of-investigational-new-drug-application-for-beam-302-for-the" rel="noreferrer noopener">ongoing Phase 1/2 trial</a>.
Price Action: BEAM stock is down 6.75% at $14.24 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44652222/trumps-tariffs-may-shift-us-spending-from-goods-to-services-creating-uncertainty-for-ecommerce-and-advertising-industries-analyst-warns" target="_blank" rel="noreferrer noopener">Tariffs To Impact End Demand: Goldman Sachs Analyst Expects Drag On Corporate Spending, Hiring</a></li>
</ul>

Biotech

News

Health Care

Movers

General

BEAM

Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and maintains $80 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

New Data Demonstrate Proportion of Corrected M-AAT Reached a Mean of 91% of Total AAT in Circulation at Day 28 Following BEAM-302 Treatment in 60 mg Cohort (n=3)
Mean Decrease of 79% in Mutant Z-AAT Observed at Day 28 in 60 mg Cohort (n=3)
Fourth Cohort Evaluating 75 mg of BEAM-302 Initiated, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at a Medical Conference in Second Half of 2025

Reported Saturday, Beam Therapeutics Reports 91% Mean Correction Of Circulating AAT Protein At Day 28 In BEAM-302 Phase 1/2 Trial For AATD

On Friday, April 4, 2025, Cathie Wood-led Ark Invest made substantial trades involving several prominent companies including Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), CRISPR Therapeutics AG (NGM: CRSP), Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>), Roblox Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>), MercadoLibre Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), and Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>).
The COIN Trade
Ark Invest purchased shares of Coinbase Global Inc across multiple ETFs. Ark Invest&#8217;s ARK Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>) bought 12,187 shares, while the ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) funds added 54,988 and 15,982 shares, respectively.
The total value of the COIN shares bought, calculated from the last closing price of $160.55, amounts to approximately $13.5 million.
The AMZN Trade
Amazon.com Inc also saw significant buying action from Ark Invest. The ARKF, ARKK, and ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) funds bought 9,018, 25,528, and 8,408 shares, respectively.
Given Amazon&#8217;s last closing price of $171.0, the total value of the shares bought is approximately $7.4 million.
The CRSP and BEAM Trades
The ARKK fund bought 69,011 shares of CRISPR Therapeutics AG and 142,713 shares of Beam Therapeutics Inc. Based on the last closing prices of $32.65 and $15.2,7, respectively, the total value of the CRSP and BEAM shares bought is approximately $3.5 million.
The PATH Trade
Ark Invest's ARKK sold 448,505 shares of UiPath, while ARKQ sold 147,575 shares. The ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) fund sold 323,575 shares, and the ARKF fund sold 434,637 shares.
The RBLX, MELI, and RPTX Trades
Ark Invest sold shares of Roblox Corp. and MercadoLibre Inc. across various ETFs. Additionally, the ARKG fund sold 32,613 shares of Repare Therapeutics Inc, valued at approximately $32,613 based on the last closing price of $1.0.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44652222/trumps-tariffs-may-shift-us-spending-from-goods-to-services-creating-uncertainty-for-ecommerce-and-advertising-industries-analyst-warns">Tariffs To Impact End Demand: Goldman Sachs Analyst Expects Drag On Corporate Spending, Hiring</a> </li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Equities

Markets

Tech

ETFs

AMZN

ARKF

ARKK

ARKQ

ARKW

COIN

CRSP

MELI

PATH

RBLX

RPTX

Cathie Wood's Ark Invest Loads Up On Amazon Amid Over 20% Decline In A Year: Offloads UiPath, Roblox

The stock market took a dive, but <a href="https://www.benzinga.com/news/25/03/44132684/cathie-woods-bold-move-8-straight-days-of-buying-beam-therapeutics-as-stock-soars-14">Cathie Wood</a> didn&#8217;t flinch. Instead of retreating, the Ark Invest CEO saw an opportunity and went on a buying spree. According to<a href="https://www.investors.com/news/cathie-wood-ark-invest-coinbase-stock-robinhood-tesla-palantir-amd-coin-hood-tsla-pltr/"> Investor&#8217;s Business Daily</a>, her firm snapped up shares of Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), and more on March 10.
<h2 class="wp-block-heading">Big Bets in a Turbulent Market</h2>
Investor&#8217;s Business Daily said that Ark Invest picked up 79,318 shares of Tesla, valued at $17.62 million based on Monday&#8217;s closing price of $222.15. The firm also acquired 269,864 shares of Robinhood for $9.6 million and 64,358 shares of Coinbase, worth $11.53 million.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
Other buys included 147,551 shares of Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) for $14.26 million, 152,253 shares of Palantir at $11.63 million, and 485,005 shares of Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), valued at $12.46 million.
It&#8217;s a familiar strategy for Wood, who has built a reputation for &#8220;buying the dip.&#8221; She firmly believes in disruptive innovation and has placed some of her biggest bets on Tesla.&nbsp;
Wood thinks part of the recent demand dip for Tesla could result from broader fears about the economy. In a recent<a href="https://www.ark-funds.com/webinars/mar-2025-fund-webinar?utm_medium=email&amp;_hsmi=353364069&amp;utm_content=353364069&amp;utm_source=hs_email"> Ark Invest webinar</a>, she said, &#8220;Now, clearly, the political dynamics of the last few months are hitting demand; we also would suggest that the economic outlook is hitting demand—not just for Tesla—but for all auto manufacturers.&#8221;&nbsp;
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
Despite the stock&#8217;s 31% decline this year and a growing list of challenges, Wood has maintained a bullish outlook. She told <a href="https://www.bloomberg.com/news/articles/2025-03-25/cathie-wood-sticks-with-tesla-predicts-stock-will-hit-2-600">Bloomberg TV</a> that Tesla&#8217;s price could soar over the next five years.
Tesla has been at the center of controversy for months. Since Elon Musk&#8217;s closer ties with the Trump administration, the electric vehicle company has faced public protests, boycotts, and even vandalism.&nbsp;
Musk&#8217;s role as an advisor to the Department of Government Efficiency has drawn criticism, with some accusing the CEO of shifting the company into politically charged territory.
See Also: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
The turmoil has had financial consequences. Tesla&#8217;s stock has been on a downward trend, while competitors, particularly China&#8217;s BYD, have continued to gain market share. According to <a href="https://edition.cnn.com/2025/03/20/business/even-used-teslas-are-falling-out-of-favor/index.html">CNN</a>, Tesla vehicles&#8217; resale value has also dropped over the past month.
Amid the backlash, President Donald Trump publicly backed Musk. He said on <a href="https://truthsocial.com/@realDonaldTrump/posts/114141854575248527">Truth Social </a>that he would buy a Tesla, calling it a &#8220;show of confidence&#8221; in the company. The move follows a broader effort by Trump&#8217;s administration to support Tesla.&nbsp;
Commerce Secretary Howard Lutnick, the commerce secretary, encouraged Americans to invest in the company.&nbsp;
&#8220;I think if you want to learn something on this show tonight, buy <a href="https://www.benzinga.com/news/25/03/44209579/unprecedented-slide-tesla-sales-plummet-45-in-europe-as-musks-net-worth-dives-5-2b-in-a-week">Tesla</a>. It&#8217;s unbelievable that this guy&#8217;s stock is this cheap. It&#8217;ll never be this cheap again,&#8221; ​he told Fox News on March 19.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>

Personal Finance

HOOD

PLTR

TSLA

Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed'

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays analyst Henning Cosman upgraded the rating for Ferrari N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>) from Equal-Weight to Overweight. Ferrari shares closed at $426.82 on Thursday. <a href="https://www.benzinga.com/quote/RACE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Blayne Curtis upgraded Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) from Hold to Buy and announced a $195 price target. Applied Materials shares closed at $147.68 on Thursday. <a href="https://www.benzinga.com/quote/AMAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Keith Bachman upgraded the rating for Check Point Software Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) from Market Perform to Outperform and raised the price target from $245 to $275. Check Point Software shares closed at $231.31 on Thursday. <a href="https://www.benzinga.com/quote/CHKP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Caitlin Burrows upgraded Tanger Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKT#NYSE">SKT</a>) from Neutral to Buy and boosted the price target from $39 to $40. Tanger shares closed at $32.86 on Thursday. <a href="https://www.benzinga.com/quote/SKT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Alec Stranahan upgraded the rating for Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Neutral to Buy and maintained the price target of $42. Beam Therapeutics shares closed at $22.19 on Thursday. &nbsp;<a href="https://www.benzinga.com/quote/BEAM/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AMAT stock? Here&#8217;s what analysts think: 
Read This Next:<a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a></li>
</ul>
Photo: Shutterstock

Upgrades

Pre-Market Outlook

Trading Ideas

AMAT

CHKP

RACE

This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Beam Therapeutics, presenting an average target of $53.89, a high estimate of $80.00, and a low estimate of $25.00. A 7.55% drop is evident in the current average compared to the previous average price target of $58.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1743163275_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Beam Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alec Stranahan</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Soumit Roy</td>
<td>Jones Trading</td>
<td>Announces</td>
<td>Buy</td>
<td>$34.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$78.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Beam Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Beam Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Beam Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Beam Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BEAM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Beam Therapeutics analyst ratings.</a>
<h2>Get to Know Beam Therapeutics Better</h2>
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 &amp; 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
<h3>Beam Therapeutics: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Beam Therapeutics's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -90.49%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -300.51%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Beam Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -11.85%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.94%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Beam Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.22, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock

B of A Securities analyst Alec Stranahan upgrades Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Neutral to Buy and maintains the price target from $42 to $42.

B of A Securities Upgrades Beam Therapeutics to Buy, Maintains Price Target to $42

U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S.
CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=CBsje_Xtz_cDfv6xJ9MGUStWgQ1d58JxqmOuiR5CJFoi__HBN6R2zqYvT7RqTyDgwhJhj8h-uqaBIvoHtT0Rslsh7A7UGCzjoOgFk5m8nhw=">Beam Therapeutics Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there are no currently approved curative treatments.
"The FDA's clearance of our IND for BEAM-302 is a significant step toward advancing the development of this potential breakthrough treatment for patients living with AATD in the U.S.," said Giuseppe Ciaramella, Ph.D., president of Beam. "Earlier this month, we shared groundbreaking initial safety and efficacy data from our global Phase 1/2 study of BEAM-302, showcasing the first ever clinical genetic correction of a disease-causing mutation. As we move forward, we're laser focused on progressing this trial to enroll and dose more patients, activating more sites in new geographies, and preparing to present updated data in the second half of the year."
BEAM-302 is a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing PiZ mutation in patients with AATD.&nbsp;BEAM-302 is being evaluated in an ongoing Phase 1/2, open-label, dose exploration and dose expansion clinical trial to investigate its safety, tolerability, pharmacodynamics, pharmacokinetics and efficacy. Part A of the trial is designed to evaluate AATD patients with lung disease, and Part B will evaluate AATD patients with mild to moderate liver disease with or without lung disease. Initial safety and efficacy results from the trial were <a href="https://www.globenewswire.com/Tracker?data=eLpUtJQDGhOT-96QV9EmjS-eqi7vNw9giS21bCU0RmnfoF1S0ygOPuAgiV7VRlCfogUhzqafvf1JUgmroUCfZMEGkZAn6EqsupOzU9FcL0GaW6hHsTC6LAl3Zp2vdcenr3t73-LPXnY7tOmtZGcoJmuqAQkohAod7bqf56xC5BVS4aS05HuNGz24TjFrM-eUtI7ApEAo2scXy6FX9UMQNE-NbIsG2MljKIBdIsUlV0U=">reported</a> in March 2025 and established proof of concept for BEAM-302 as a potential one-time treatment for AATD. In addition to the U.S., BEAM-302 has received clinical trial authorization from the United Kingdom, New Zealand, Australia, the Netherlands and Ireland.

Beam Therapeutics Announces Clearance Of Investigational New Drug Application For BEAM-302 For Treatment Of Alpha-1 Antitrypsin Deficiency By The U.S. FDA

On Friday, March 21, 2025, the Cathie Wood-led Ark Invest made some notable trades, including significant buys and sells.
Ark Invest's fund bought Iridium Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>), Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), Pacific Biosciences of California Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) and Absci Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>), while selling Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>).
The IRDM Trade: Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>), and ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) funds purchased a total of 68,355 shares of Iridium Communications Inc.
The total value of the shares bought, based on the last close price of $27.65, is approximately $1.89 million.
The BEAM Trade: Ark Invest&#8217;s ARKK and Ark Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) funds bought a total of 28,717 shares of Beam Therapeutics Inc.
The total value of the shares bought, based on the last close price of $23.3, is approximately $669,106.
The PACB Trade: Ark Invest&#8217;s ARKK fund bought a whopping 243,300 shares of Pacific Biosciences of California Inc.
The total value of the shares bought, based on the last close price of $1.3, is approximately $316,290.
Other Key Trades:
<ul>
<li>Illumina Inc: Ark Invest sold a total of 42,616 shares through ARKK and ARKG.</li>
<li>Absci Corp: Ark Invest&#8217;s bought 71,392 shares through ARKG.</li>
<li>Repare Therapeutics: Ark Invest sold 54,786 shares through ARKG.</li>
<li>Amgen Inc: Ark Invest sold 990 shares through ARKG.</li>
<li>Veeva Systems Inc: Ark Invest sold 1,322 shares through ARKG.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44434973/tesla-record-highest-trade-ins-amid-backlash-against-ceo-elon-musk-surge-in-vandalism">Tesla Record Highest Trade-Ins Amid Backlash Against CEO Elon Musk, Surge In Vandalism</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

ABSI

AMGN

ARKG

ARKX

ILMN

IRDM

PACB

VEEV

Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen

Cantor Fitzgerald analyst Rick Bienkowski reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Overweight to Overweight.

Cantor Fitzgerald Reiterates Overweight on Beam Therapeuticsto Overweight

Scotiabank analyst Greg Harrison upgrades Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Sector Perform to Sector Outperform and announces $40 price target.

Scotiabank Upgrades Beam Therapeutics to Sector Outperform, Announces $40 Price Target

Jones Trading analyst Soumit Roy upgrades Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Hold to Buy and announces $34 price target.

Jones Trading Upgrades Beam Therapeutics to Buy, Announces $34 Price Target

On Monday, Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in <a href="http://Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains" target="_blank" rel="noreferrer noopener">vivo base editing</a>.
The initial safety and efficacy data reported are from all nine patients as of February 26, the data <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44214548/beam-therapeutics-announces-positive-initial-data-for-beam-302-in-the-phase-12-trial-in-alpha-1-an" rel="noreferrer noopener">cut-off date</a>.
Preliminary results from the first three single-ascending dose cohorts demonstrated that BEAM-302 was well tolerated, with single doses of BEAM-302 leading to durable dose-dependent correction of the disease-causing mutation.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42393770/beam-therapeutics-unveils-new-safety-efficacy-data-from-sickle-cell-disease-candidate-stock-gains" rel="noreferrer noopener">Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains</a>
Alpha-1 antitrypsin (AAT) deficiency is&nbsp;a genetic disorder that can cause lung disease and liver disease.&nbsp;It occurs when the body doesn&#8217;t produce enough AAT, a protein that protects the lungs and liver.&nbsp;
Following a single infusion of BEAM-302, rapid, durable and dose-dependent increases in total AAT, a new production of corrected M-AAT and decreases in mutant Z-AAT were observed in circulation.
<ul>
<li>Changes in total AAT were observed as early as Day 7, plateaued around Day 21 and were maintained for the duration of follow-up (up to Month 6 in the 15 mg cohort, Month two in the 30 mg cohort and Day 28 in the 60 mg cohort).</li>
<li>Increased total AAT was functional.</li>
</ul>
Beam plans to continue the dose-escalation portion of Part A of the ongoing Phase 1/2 trial, including enrolling and dosing a fourth dose cohort. It also expects to report further data at a medical conference in the second half of 2025.
In addition, the company plans to dose the first patient in Part B, including AATD patients with mild to moderate liver disease, in the second half of 2025.
Concurrently, Beam Therapeutics priced the underwritten offering of 16.15 million shares at $28.48 per share and pre-funded warrants to purchase 1.4 million at $28.47 per pre-funded warrant, with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44214581/beam-therapeutics-announces-pricing-of-underwritten-offering" rel="noreferrer noopener">approximately $500 million gross proceeds</a>.
Price Action: BEAM stock is down 3.44% at $27.50 during the premarket session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44217345/whats-going-on-with-palantir-stock-premarket-on-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Palantir Stock Premarket On Monday?</a></li>
</ul>
Photo: Shutterstock

Financing

Offerings

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

WIIM

Beam Therapeutics shares are trading lower after the company announced a $500 million offering.

Beam Therapeutics Priced Underwritten Offering Of 16.15M Shares At $28.48 Per Share, And Pre-funded Warrants To Purchase 1.40M Shares At $28.47 Per Pre-funded Warrant, With Gross Proceeds Of Of Approximately $500M

<ul>
<li>Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across Initial Three Dose Levels</li>
<li>Third Dose Level of BEAM-302 (60 mg, N=3) Achieved Mean Total AAT of 12.4µM at Day 28, Exceeding Protective Therapeutic Threshold, and Reduced Mutant Z-AAT up to 78%</li>
<li>Initial Safety Findings Demonstrated BEAM-302 was Well Tolerated at All Dose Levels with No Serious Adverse Events or Dose-Limiting Toxicities Observed</li>
<li>Clinical Profile Supports Continued Dose Escalation, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at Medical Conference in Second Half of 2025</li>
</ul>

Beam Therapeutics Announced Initial Safety And Efficacy Data From Its Phase 1/2 Trial Of BEAM-302, As Potential Treatment For Alpha-1 Antitrypsin Deficiency And For In Vivo Base Editing

Cathie Wood is back in the spotlight, and so is her flagship ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>). After a rough year, the fund is showing <a href="https://portfolioslab.com/symbol/ARKK">signs of life</a>—but is this the start of a real comeback, or just another short-lived rally? <a href="https://www.benzinga.com/startups/25/02/43466203/warren-buffetts-127-billion-stock-sell-off-sends-wall-street-a-stark-warning-for-2025-below-average-returns-ahead">Investors</a> are split, and the numbers tell an interesting story.
<h2 class="wp-block-heading">ARKK's Rebound, Skeptics, and the High-Stakes Bet on Innovation</h2>
So far this year, ARKK is up 6%—a solid lead over the S&amp;P 500's 2% gain and the Nasdaq's 1% increase. That's a welcome shift after 2024, when ARKK returned 12%—not bad, but nowhere near the S&amp;P 500's 24% surge.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/startengine-own">The $1.3 Billion Startup Investment Boom: How This Company's Explosive Growth Is Opening Doors For Everyday Investors With A New $500 Minimum</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
Looking at the bigger picture, ARKK's longer-term numbers tell a more complicated story. Over the past three years, its annualized return is -5.89%, and its five-year return barely hits 1.03%. By comparison, the S&amp;P 500 has delivered 13.14% and 14.27% over the same periods.&nbsp;
That's why some investors are still wary—last year, ARKK saw nearly $3 billion in outflows, as<a href="https://finance.yahoo.com/news/cathie-wood-sells-19-million-215254938.html"> Yahoo Finance</a> reports.
Michael Burry, best known for predicting the 2008 financial crisis, has been one of ARKK's loudest critics. He argues that many of its holdings burn through cash at unsustainable rates, and at one point, he even shorted the fund. Burry sees ARKK as too dependent on speculative growth stocks with shaky profitability.
Trending: <a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a>
Morningstar analyst&nbsp; Robby Greengold has also been skeptical of ARK Invest. Greengold downgraded the ARK Innovation ETF to a negative rating, citing concerns over risk management and portfolio concentration.
He believes the firm lacks structured risk management and relies too much on aggressive forecasting. The strategist <a href="https://www.channelchek.com/news-channel/morningstar_analyst_peeks_behind_aark_curtain_and_calls_fund_wretched">outlines his concerns</a>, pointing out that while Wood's strategy is bold, it also lacks a benchmarking strategy.
But Wood isn't backing down. She believes that regulatory rollbacks and technological advancements will fuel long-term innovation, and she's sticking to her guns. On Feb. 20, ARK Invest <a href="https://www.investing.com/news/company-news/cathie-woods-ark-buys-beam-therapeutics-sells-adaptive-biotech-stock-93CH-3882383">bought another 170,778 shares</a> of Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), a move that reinforces her faith in genomics and precision medicine.<a href="https://www.investing.com/news/company-news/cathie-woods-ark-buys-beam-therapeutics-sells-adaptive-biotech-stock-93CH-3882383?utm_source=chatgpt.com">&nbsp;</a>
See Also: Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a>
ARK now holds nearly 7.7 million shares of Beam, making up 8.54% of the company's outstanding stock. That investment places Beam as ARK's 20th largest position, per<a href="https://www.marketbeat.com/instant-alerts/ark-investment-management-llc-has-17529-million-stake-in-beam-therapeutics-inc-nasdaqbeam-2025-02-26/"> MarketBeat</a>. Not everyone is convinced. Short-sellers warn that biotech companies like Beam face steep financial challenges.&nbsp;
Jim Chanos, known for spotting overvalued stocks, believes ARK often gets caught up in hype without clear paths to profitability. While ARK supports disruptive innovation, Chanos said many of these companies are valued based on hype rather than fundamentals, making them risky long-term bets.
Read Next:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

Short Sellers

Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14%

Scotiabank analyst Greg Harrison maintains Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Sector Perform and raises the price target from $24 to $25.

Scotiabank Maintains Sector Perform on Beam Therapeutics, Raises Price Target to $25

Press Releases

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Earnings

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Beam Therapeutics Announces Pricing of Underwritten Offering

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Comments

Beam Therapeutics

ニュース

最新ニュース Beam Therapeutics (NASDAQ:BEAM) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル